Skip to main content

10 Result(s)

within Shota Omori Remove this filter Medicine & Public Health Remove this filter Cancer Research Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor

    It is unclear whether there is a difference in the effect of gefitinib treatment between patients with postoperative recurrent non-small cell lung cancer (NSCLC) and those with stage IV NSCLC harboring mutatio...

    Ryo Ko, Hirotsugu Kenmotsu, Yasushi Hisamatsu… in International Journal of Clinical Oncology (2015)

  2. No Access

    Article

    The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum

    This study was to determine the incidence and risk factors of febrile neutropenia in chemotherapy-naïve Japanese patients treated systemically with etoposide plus platinum for lung cancer.

    Takumi Fujiwara, Hirotsugu Kenmotsu, Tateaki Naito… in Cancer Chemotherapy and Pharmacology (2017)

  3. No Access

    Article

    Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer

    Currently, no markers predictive of response to nivolumab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) are currently recognized in Japan. The present study was undertaken to identif...

    Haruki Kobayashi, Shota Omori… in International Journal of Clinical Oncology (2017)

  4. No Access

    Article

    Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer

    Despite the efficacy of postoperative adjuvant cisplatin (CDDP)-based chemotherapy for patients who have undergone surgical resection of non-small cell lung cancer (NSCLC), few reports have presented survival ...

    Hirotsugu Kenmotsu, Yasuhisa Ohde, Kazushige Wakuda… in Cancer Chemotherapy and Pharmacology (2017)

  5. No Access

    Article

    Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments

    The expression of programmed death ligand 1 (PD-L1) is considered a predictive biomarker of anti-programmed death 1 (PD-1)/PD-L1 cancer therapies. However, changes in PD-L1 expression of tumor cells during cli...

    Shota Omori, Hirotsugu Kenmotsu, Masato Abe… in International Journal of Clinical Oncology (2018)

  6. No Access

    Article

    Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity

    Severe hepatotoxicity induced by the standard dose of gefitinib (250 mg daily) often becomes manageable by dose reduction to 250 mg every other day. Thus, we hypothesized that systemic exposure of standard-dos...

    Takahisa Kawamura, Chiyo K. Imamura… in Cancer Chemotherapy and Pharmacology (2020)

  7. No Access

    Article

    Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy

    The expression of programmed cell death-ligand 1 (PD-L1) is a biomarker for administering immune check point inhibitors in patients with advanced stage non-small cell lung cancer. Although the consolidation th...

    Nobuaki Mamesaya, Koji Muramatsu… in International Journal of Clinical Oncology (2021)

  8. No Access

    Article

    Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancer

    This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced non-small cell lung cancer (NSCLC).

    Hideyuki Harada, Shota Omori, Keita Mori… in International Journal of Clinical Oncology (2022)

  9. No Access

    Article

    Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients

    To evaluate the relationship between treatment efficacy and exposure of total and unbound erlotinib in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-activating...

    Hirotsugu Kenmotsu, Chiyo K. Imamura… in Cancer Chemotherapy and Pharmacology (2022)

  10. No Access

    Article

    Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments

    Trophoblast cell-surface antigen 2 (TROP2) is expressed on the surface of trophoblast cells and many malignant tumor cells. However, data on TROP2 expression in advanced lung cancer are insufficient, and its c...

    Shota Omori, Koji Muramatsu, Takuya Kawata… in Journal of Cancer Research and Clinical On… (2022)